Navigation Links
Marshall Edwards Receives Positive Response From NASDAQ
Date:3/16/2011

SAN DIEGO, March 16, 2011 /PRNewswire/ -- Marshall Edwards, Inc.(Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that it has received a positive response from the NASDAQ Listing Qualifications Panel indicating that the Company's request for a transfer and continued listing on The NASDAQ Capital Market has been granted pending verification by the Listing Qualifications Staff. The Company's securities will begin trading on The NASDAQ Capital Market effective with the open of business today, March 16, 2011.

The NASDAQ Capital Market is a continuous trading market that operates in substantially the same manner as The NASDAQ Global Market. All companies listed on The NASDAQ Capital Market must meet certain financial requirements and comply with NASDAQ's corporate governance requirements. The transfer of the Company's listing from The NASDAQ Global Market to The NASDAQ Capital Market should have no impact on trading in the Company's shares, and the Company's stock will continue to trade on NASDAQ under the symbol MSHL.

About Marshall Edwards

Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes lead drug candidate NV-143. The second is a mitochondrial inhibitor program that includes NV-128 and its next-generation candidate NV-344. Both programs are expected to advance into the clinic in 2011. For more information, please visit www.marshalledwardsinc.com.


'/>"/>
SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Marshall Edwards to Host Annual Meeting of Stockholders
2. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
3. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
4. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
5. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
6. Cynosure Receives International Marketing Clearances for New Cellulite, Laser Lipolysis Products
7. The Balance-Based Torso-Weighting® Treatment for Multiple Sclerosis Receives a NIH Recovery Act Grant
8. China Botanic Pharmaceutical Receives a Tax Exemption in 2011
9. SCOLR Pharma, Inc. Receives Deficiency Letter from FDA on Pseudoephedrine Application
10. ULURU Inc. Receives Letter of Non-Compliance From NYSE Amex
11. Sonitus Medical Receives European CE Mark for SoundBite™ Hearing System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... EDMONTON, Alberta , July 21, 2017 ... the University of Alberta in Edmonton, ... Nature,s partner journal, Schizophrenia 1 , demonstrating that ... of schizophrenia with 74% accuracy. This retrospective analysis ... specific symptoms in schizophrenia patients with significant correlation, ...
(Date:7/20/2017)... PAUL, Minn. , July 20, 2017  Prime Therapeutics ... Jonathan Gavras , M.D., following today,s Institute for Clinical ... report on the effectiveness and value of abuse-deterrent ... manager on the policy roundtable at the meeting. ... is not a material cost benefit to the use of ...
(Date:7/14/2017)... , July 14, 2017 Endo International plc (NASDAQ: ... Tuesday, August 8, 2017.  Members of its senior management team will ... open at 8:30 a.m. ET. The dial-in number ... 497-0462, International (678) 509-7598, and the passcode is 45397076. Please dial ... A replay of the call will ...
Breaking Medicine Technology:
(Date:7/26/2017)... ... ... Six greater Bay Area roller derby leagues are partnering with Brown Paper Tickets and the ... of blood drives in California, beginning July 29. Make ‘Em Bleed roller derby blood drives ... to have helped to save up to 2700 lives. , “The Make ‘Em Bleed blood ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... (ISPE) will host its 2017 Process Validation and Process Validation Statistics ... comprehensive solutions to process validation lifecycle challenges faced by process validation professionals ...
(Date:7/26/2017)... ... July 26, 2017 , ... A global ... in Jupiter. The state of the art center will provide advanced surgical ... a goal of providing heart patients longer lives. , North American Veterinary Heart ...
(Date:7/26/2017)... , ... July 26, 2017 , ... ... innovative specialty pharmacies, has released an updated version of the HCV Treatment Path ... for treating chronic hepatitis C virus (HCV) infection. All of the latest HCV ...
(Date:7/25/2017)... (PRWEB) , ... July 25, 2017 , ... ... to announce the launch of their partnership to provide the Pharmacist eCare ... first pharmacy-focused platform in the country with the ability to develop the Pharmacist ...
Breaking Medicine News(10 mins):